| 9.08 -0.07 (-0.77%) | 06-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.17 | 1-year : | 13.05 |
| Resists | First : | 9.56 | Second : | 11.17 |
| Pivot price | 8.55 |
|||
| Supports | First : | 8.27 | Second : | 7.46 |
| MAs | MA(5) : | 8.5 |
MA(20) : | 8.46 |
| MA(100) : | 6.44 |
MA(250) : | 5.94 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 55.8 |
D(3) : | 32.9 |
| RSI | RSI(14): 61.3 |
|||
| 52-week | High : | 9.56 | Low : | 4.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CADL ] has closed below upper band by 15.3%. Bollinger Bands are 6.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.33 - 9.37 | 9.37 - 9.41 |
| Low: | 8.85 - 8.9 | 8.9 - 8.94 |
| Close: | 9 - 9.08 | 9.08 - 9.15 |
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Sun, 21 Jun 2026
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to S&P Biotechnology Select Industry Index - marketscreener.com
Sun, 21 Jun 2026
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Tue, 16 Jun 2026
Candel Therapeutics (NASDAQ: CADL) sets new pay and severance package for CFO - Stock Titan
Mon, 15 Jun 2026
Candel Therapeutics Faces Strategic Financial Moves Amidst Stock Offering - timothysykes.com
Mon, 01 Jun 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 73 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 15.7 (%) |
| Held by Institutions | 59.7 (%) |
| Shares Short | 14,160 (K) |
| Shares Short P.Month | 14,680 (K) |
| EPS | -1.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.87 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.7 % |
| Return on Equity (ttm) | -51.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -48 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -9 |
| PEG Ratio | 0 |
| Price to Book value | 4.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|